Vaccine Microarray Patch

Technical Development

According to the market report (Greystone, 2016), MAP has great potential to grow into a large market, particularly for vaccines. WCC is cooperating with the National Health Research Institute (NHRI),the objective is to combine the advanced B5 type vaccine developed by NHRI for Endovirus 71 type with the MAP by WCC. NHRI has organized an “Asian Endovirus Detection League”, which includes 8 countries such as vietnam, Malaysia and so on. The new borns in these countries can benefit from the MNP Vaccines in the future.


Endovirus MNP EV71 type vaccine/ Flu/Others


1. The amount of vaccine can be substantially reduced to less than 20 %.
2. Painless application is highly acceptable.
3. No need to go to hospitals.
4. MNP is in solid form, no need for low-temperature storage, transportation is much cheaper the cost (cold chain is substantially reduced).


R&D / ODM / others

The vaccine microneedle patch has irreplaceable advantages such as being able to be transported at room temperature, and the dosage is only 20% of the traditional injection. American national institutions such as BARDA (Biomedical Advanced Research and Development Authority) have invested considerable resources to support the development of many companies such as Vaxess and Vaxxas COVID-19 vaccine patch. Among them, Vaxess company has received a number of grants from the US government and the Bill Gates Foundation.

Further Reading:Vaccine Microarray Patches (VMAPs)